Home › Blog › Weight Loss › Can I Get Weight Loss Injections on the NHS?
Can I Get Weight Loss Injections on the NHS? The Complete 2026 Guide
No NHS Waiting List — Mounjaro and Wegovy Delivered Tomorrow
Same MHRA-licensed medication as the NHS · GPhC No. 1033729 · NHS-contracted · Fixed 2026 prices · Free monthly clinical check-ins
- ✅ Mounjaro 2.5mg £139 → 15mg £285 · Wegovy 0.25mg £99.99 → 2.4mg £209.99
- ✅ Free starter pack (needles + sharps bin) · Free monthly check-ins · £4.99 delivery
- ✅ No subscription · No minimum term · Next-day cold-chain to every UK postcode
- ✅ GPhC No. 1033729 · NHS-contracted · SCOPE Obesity Accredited · LegitScript Certified
The Quick Answer
Yes — you can get weight loss injections on the NHS in 2026. But the route you take, how long you wait, and whether you pay anything depends on three factors: where you live, your clinical profile, and which of the three NHS routes applies to you.
Most people think there is only one NHS route. In 2026, there are three — and the April 2026 changes opened two faster routes that the majority of eligible patients have not yet used. This guide explains all three, what changed, who qualifies, what the waiting times actually are, and how to run the NHS and private routes simultaneously.
The Three NHS Routes for Weight Loss Injections in 2026
Tier 3 Specialist Weight Management — Via GP Referral
⏱ Wait: 12–36 months depending on your ICB — the most common route but also the slowest
The primary NHS route. Your GP refers you to your local integrated care board’s (ICB) tier 3 specialist weight management service. Once referred and assessed by the tier 3 team, you can receive Mounjaro or Wegovy on NHS prescription.
Eligibility under NICE TA1026 (Mounjaro) and NICE TA875 (Wegovy):
- BMI 35 or above with at least one qualifying condition: type 2 diabetes, hypertension, cardiovascular disease, high cholesterol, sleep apnoea, NAFLD, PCOS, or obesity-related osteoarthritis
- Previous engagement with tier 1 and tier 2 weight management programmes (requirement varies by ICB)
- GP referral required — your GP sends a referral to the tier 3 service
- NHS prescription charge: £9.90 per item in England (free in Scotland)
The most important action if this is your route: ask your GP for a tier 3 referral TODAY. Every week without a referral is a week added to an already long wait. Even if you plan to start Slinic simultaneously, get on the NHS list now.
GP Direct Cardiovascular Pathway — Wegovy for CVD Patients
⚡ Wait: Potentially weeks at GP level — bypasses tier 3 entirely
The April 2026 cardiovascular change is one of the most significant updates in UK weight loss medicine. Following NICE’s April 2026 guidance based on the SELECT trial (20% reduction in major cardiovascular events, NEJM 2023), GPs in England can now prescribe Wegovy directly for patients who meet all three criteria:
- BMI 27 or above
- Established cardiovascular disease: prior myocardial infarction, prior stroke or TIA, or peripheral arterial disease
- No type 2 diabetes
This bypasses tier 3 referral entirely. Adoption varies by practice — some GPs are already prescribing through this route, others are still in implementation. If you have had a heart attack, stroke, or TIA and your BMI is 27 or above, ask your GP today: “Am I eligible for the NICE April 2026 cardiovascular semaglutide prescribing pathway?”
QOF Type 2 Diabetes Pathway — Mounjaro for T2D Patients
⚡ Wait: Potentially weeks — GP practice must have adopted the pathway
From April 2026, Mounjaro (tirzepatide) is incorporated into the NHS GP Quality and Outcomes Framework (QOF) for type 2 diabetes. GP practices that have adopted the pathway can prescribe Mounjaro for T2D patients without a tier 3 referral.
- Having type 2 diabetes is the qualifying criterion
- GP practice must have adopted the QOF T2D Mounjaro pathway — rollout is ongoing
- Mounjaro holds a dual licence: for weight management AND type 2 diabetes control simultaneously
- BMI threshold may vary by practice pathway — discuss with your GP
If you have type 2 diabetes, ask your GP: “Has your practice adopted the QOF tirzepatide T2D prescribing pathway?” This pathway is especially transformative in high-T2D areas including Bradford (10% T2D — highest in England), Tower Hamlets, Newham, Birmingham (9.5%), and Oldham.
Step 1: Ask your GP today for a tier 3 referral (Route 1). Start the NHS clock now.
Step 2: Ask your GP about the April 2026 cardiovascular Wegovy pathway (Route 2) if you have established CVD.
Step 3: Ask your GP about the QOF T2D Mounjaro pathway (Route 3) if you have T2D.
Step 4: Start Slinic’s private route simultaneously — medication delivered tomorrow. Starting private does not affect your NHS position.
Full NHS Eligibility Criteria — Who Qualifies for What
| NHS Route | BMI requirement | Additional criteria | Medication | Who prescribes |
|---|---|---|---|---|
| Tier 3 weight management | BMI 35+ | At least 1 qualifying condition · Previous tier 1/2 engagement (varies by ICB) | Mounjaro or Wegovy | Tier 3 specialist service after GP referral |
| April 2026 cardiovascular GP pathway | BMI 27+ | Established CVD (prior MI, stroke/TIA, or PAD) · No type 2 diabetes | Wegovy only | GP directly — no tier 3 referral needed |
| QOF T2D GP pathway (April 2026) | BMI varies by practice | Type 2 diabetes · GP practice must have adopted pathway | Mounjaro only | GP directly — no tier 3 referral needed |
Qualifying conditions for tier 3 eligibility
At least one of the following must be present for tier 3 referral alongside BMI 35+:
- Type 2 diabetes (T2D)
- Hypertension (high blood pressure) — diagnosed and on medication
- Cardiovascular disease — prior MI, stroke, or other cardiovascular event
- High cholesterol (dyslipidaemia)
- Obstructive sleep apnoea (diagnosed)
- Non-alcoholic fatty liver disease (NAFLD)
- Polycystic ovary syndrome (PCOS)
- Obesity-related osteoarthritis
Real NHS Waiting Times by Region — 2026
| Region / ICB | Tier 3 wait (approximate) | Notes |
|---|---|---|
| North East London ICB (Tower Hamlets, Newham, Hackney) | 18–36 months | Longest in England. Highest T2D burden (Tower Hamlets ~12–14%). April 2026 QOF T2D pathway most impactful in England for this area. |
| NHS Cheshire and Merseyside ICB (Liverpool) | 18–30 months | Knowsley has England’s highest local authority obesity rate (~40%+). Above-average CVD. April 2026 CVD Wegovy pathway highly relevant. |
| NHS Birmingham and Solihull ICB | 18–24 months | City-wide T2D ~9.5%. Ward-level rates in Sparkbrook and Small Heath exceed 20%. QOF T2D pathway most impactful of any major English city. |
| NHS Black Country ICB (Wolverhampton, Sandwell, Dudley, Walsall) | 16–22 months | Post-industrial health legacy. Above-average CVD and obesity. April 2026 CVD Wegovy pathway relevant. |
| NHS Greater Manchester ICB | 12–24 months | Varies widely: 12 months in Trafford and Stockport; 18–24 months in Oldham and Wigan. Oldham has large South Asian community — ethnic BMI adjustments critical. |
| NHS South East London ICB (Lambeth, Lewisham, Southwark) | 18–30 months | Significant Black African/Caribbean communities. Above-average CVD and T2D. Ethnic BMI adjustments relevant. |
| NHS West Yorkshire ICB — Bradford locality | 14–20 months | Bradford has England’s highest T2D rate (~10%) driven by its large Pakistani community. QOF T2D pathway critical here. |
| NHS West Yorkshire ICB — Leeds locality | 12–18 months | Shorter than Bradford. Above-average rates in Chapeltown and Harehills. |
| NHS South Yorkshire ICB (Sheffield, Rotherham, Barnsley, Doncaster) | 12–20 months | Page Hall (S4) has large Pakistani and Somali community — ethnic BMI adjustments. 12 months in Sheffield City, 14–20 in other areas. |
| NHS Nottingham and Nottinghamshire ICB | 12–24 months | 12–18 months in Nottingham City; 16–24 months in Mansfield and outer Nottinghamshire. South Asian community in Hyson Green — ethnic adjustments apply. |
| NHS North Central London ICB (Haringey, Enfield, Barnet, Camden, Islington) | 12–24 months | Turkish and Kurdish community in Haringey and Enfield — ethnic adjustments relevant. Camden and Islington shorter waits than outer areas. |
| NHS North West London ICB (Harrow, Brent, Ealing, Hounslow, Hillingdon) | 12–30 months | Harrow ~65% South Asian — ethnic BMI adjustments apply to majority of patients. Brent, Ealing, Hounslow similarly high South Asian populations. |
| NHS South West London ICB (Croydon, Kingston, Richmond, Merton, Wandsworth, Sutton) | 12–24 months | Shortest in London overall. Richmond and Kingston ~12–18 months. Croydon longer due to higher demand and diverse population. |
| NHS BNSSG ICB (Bristol, North Somerset, South Gloucestershire) | 12–18 months | Shortest in England. Significant Somali community in Bristol (St Pauls, Easton) — ethnic adjustments relevant. |
| NHS Lothian (Edinburgh) | 12–24 months | Scotland — NHS prescriptions FREE. SMC governance not NICE. Free prescriptions make NHS route highly valuable — bridge strategy particularly strong here. |
| NHS Greater Glasgow and Clyde | 12–24 months | Scotland — NHS prescriptions FREE. Glasgow has highest obesity rate of any major UK city (~34%) and highest CVD mortality. Bridge strategy critical given 12–24 month wait and free NHS prescription at end. |
What Changed in April 2026 — The Routes Most Patients Don’t Know About
April 2026 was the most significant month for NHS weight loss injection access since Mounjaro was first approved. Two changes happened simultaneously that most patients — and many GPs — have not yet fully absorbed.
Change 1: The SELECT trial cardiovascular approval for Wegovy
The SELECT trial (Lincoff AM et al., NEJM 2023) enrolled 17,604 patients with established cardiovascular disease (prior MI, stroke, or peripheral arterial disease) and BMI 27+ but no T2D. Semaglutide 2.4mg (Wegovy) reduced major adverse cardiovascular events (MACE — heart attack, stroke, or cardiovascular death) by 20% over 34 months compared to placebo.
NICE published updated guidance in April 2026 allowing GPs to prescribe Wegovy directly for patients meeting this profile. This is a fast route: no tier 3 referral, no 12–36 month wait. It operates entirely at GP level.
Who it applies to in practice: Any patient in England with BMI 27+, a documented history of MI, stroke/TIA, or PAD, and no T2D diagnosis. This is a substantial patient population — heart disease is the UK’s leading cause of death, and many cardiac patients in the overweight-to-obese BMI range now qualify for Wegovy at GP level.
Change 2: Mounjaro in the NHS QOF for T2D
The NHS Quality and Outcomes Framework (QOF) for 2026/27 incorporated tirzepatide (Mounjaro) into the T2D management pathway. GP practices that have adopted this pathway can prescribe Mounjaro for eligible T2D patients — creating a route that, in principle, operates as fast as a GP appointment.
Adoption across England is ongoing and uneven. Some practices have fully implemented the pathway. Others are still preparing. The key question to ask your GP: “Has your practice adopted the QOF tirzepatide T2D prescribing pathway?”
Mounjaro’s dual licence — for weight management AND T2D — makes this uniquely powerful. A T2D patient starting Mounjaro gains exceptional glycaemic control (SURPASS-2 trial: HbA1c reduction of 2.58 percentage points at 15mg — the strongest of any approved T2D treatment) alongside 22.5% average weight loss.
Scotland — The Free Prescription Difference
Scotland operates a separate NHS governance structure under NHS Scotland, with medication approved by the Scottish Medicines Consortium (SMC) rather than NICE. The practical differences for Scottish weight loss injection patients are significant:
| Factor | England | Scotland |
|---|---|---|
| Approval body | NICE | SMC (Scottish Medicines Consortium) |
| Mounjaro approval | NICE TA1026 (June 2025) | SMC approved — broadly similar criteria |
| Wegovy approval | NICE TA875 (2023) + April 2026 cardiovascular | SMC approved — discuss cardiovascular pathway with GP |
| NHS prescription charge | £9.90 per item (free with exemptions) | FREE — no prescription charge for any medicine in Scotland |
| Mounjaro/Wegovy NHS cost to patient | £9.90 per pen (or free with exemptions including T2D) | £0 |
| Waiting time | Varies 12–36 months | NHS Lothian: 12–24 months · NHSGGC: 12–24 months |
| Private prescriptions valid? | Yes | Yes — GPhC-registered providers like Slinic prescribe legally to all Scottish patients |
Private Weight Loss Injections — Fixed 2026 Prices at Slinic
Same MHRA-licensed medication from authorised UK supply chains. Fixed 2026 prices. No subscription. Free monthly clinical check-ins. Next-day cold-chain to every UK postcode including all Scottish postcodes.
| Medication and dose | Slinic price | Delivery | Monthly total | Clinical stage |
|---|---|---|---|---|
| Mounjaro 2.5mg | £139.00 | £4.99 | £143.99 | Starting dose (weeks 1–4). Free starter pack. Appetite quietens within 1–2 weeks. |
| Mounjaro 5mg | £165.00 | £4.99 | £169.99 | First therapeutic dose (weeks 5–8). Weight loss accelerating. |
| Mounjaro 7.5mg | £225.00 | £4.99 | £229.99 | Mid-escalation. ~8–9% cumulative average weight loss. |
| Mounjaro 10mg | £255.00 | £4.99 | £259.99 | Upper escalation. 19.5% average weight loss at this dose in SURMOUNT-1. |
| Mounjaro 12.5mg | £275.00 | £4.99 | £279.99 | High maintenance. Near-maximum efficacy. |
| Mounjaro 15mg | £285.00 | £4.99 | £289.99 | Maximum dose. 22.5% average weight loss at 72 weeks (SURMOUNT-1, NEJM 2022). 57% of patients achieved 20%+. |
| Wegovy 0.25mg | £99.99 | £4.99 | £104.98 | Starting dose. Free starter pack included. |
| Wegovy 0.5mg | £109.99 | £4.99 | £114.98 | Month 2. Appetite suppression increasing. |
| Wegovy 1mg | £114.99 | £4.99 | £119.98 | Month 3. Entering therapeutic range. |
| Wegovy 1.7mg | £159.99 | £4.99 | £164.98 | Month 4. ~10–12% cumulative average loss. |
| Wegovy 2.4mg | £209.99 | £4.99 | £214.98 | Maintenance. 14.9% average (STEP 1, NEJM 2021). NICE cardiovascular approval April 2026. |
Each pen contains 4 weekly doses. Fixed 2026 prices verified June 2026. No subscription, no minimum term. Compare: MedExpress £179.99 starting · Boots £176.97 starting · Voy £167+ with subscription required.
No NHS Waiting List at Slinic
Mounjaro from £139 · Wegovy from £99.99 · Next-day to every UK postcode · Free monthly check-ins · GPhC No. 1033729 · NHS-contracted
The Bridge Strategy — How to Run Both Routes Simultaneously
The bridge strategy is the single most important insight in this guide. It works because the two routes — NHS and private — do not conflict with each other in any way.
The bridge strategy is the single most important insight in this guide. It works because the two routes — NHS and private — do not conflict with each other in any way.
- Ask your GP for an NHS tier 3 referral today. Start the NHS clock immediately. Also ask about the April 2026 cardiovascular Wegovy pathway (if you have established CVD) and the QOF T2D Mounjaro pathway (if you have T2D). Every day without a referral is a day added to an already long wait.
- Start Slinic’s private route simultaneously. Complete the free 2-minute eligibility assessment. If eligible, medication is at your address tomorrow. You begin losing weight during the NHS wait — not after it.
- Receive private Slinic treatment for 12–36 months while waiting. Free monthly clinical check-ins track your progress and build a complete clinical record.
- When your NHS appointment arrives, transition to NHS supply. England: £9.90 per item (or free with T2D exemption, age 60+, qualifying benefits). Scotland: free. No restart from the lowest dose — you transition at your current dose. Your Slinic records provide the tier 3 team with a full treatment history.
Mounjaro vs Wegovy on the NHS — Which Is Prescribed Through Which Route?
| Medication | NHS Route 1 (tier 3) | NHS Route 2 (April 2026 CVD) | NHS Route 3 (April 2026 T2D QOF) | Key clinical data |
|---|---|---|---|---|
| Mounjaro (tirzepatide) | ✅ Yes — prescribed through tier 3 services | ❌ Not approved for CVD route | ✅ Yes — the primary QOF T2D medication | 22.5% average weight loss at 15mg · HbA1c reduction 2.58pp · Dual weight + T2D licence |
| Wegovy (semaglutide 2.4mg) | ✅ Yes — prescribed through tier 3 services | ✅ Yes — the April 2026 CVD route medication | ❌ Not approved for the QOF T2D route | 14.9% average weight loss · 20% MACE reduction (SELECT trial) · NICE CVD approval April 2026 |
SURMOUNT-5: Head-to-head
The SURMOUNT-5 trial (NEJM 2025) compared Mounjaro 15mg directly against Wegovy 2.4mg in patients without T2D. Mounjaro produced 20.2% average weight loss versus 13.7% for Wegovy — a 47% relative difference in weight loss. For patients without T2D, Mounjaro produces significantly greater weight loss. For patients with established CVD and no T2D, the April 2026 Wegovy pathway provides a cardiovascular benefit label that Mounjaro does not yet have.
Ethnic Group BMI Adjustments — Critical for Millions of UK Patients
This section is essential reading for patients from South Asian, Black African/Caribbean, Chinese, Middle Eastern, or Somali backgrounds. The standard BMI thresholds (BMI 30+, or BMI 27+ with a condition) are derived from white European reference populations. For many non-European ethnic groups, metabolic risk — particularly T2D and cardiovascular risk — manifests at significantly lower BMIs.
| Ethnic background | Standard threshold | Adjusted threshold at Slinic | Clinical basis |
|---|---|---|---|
| South Asian (Pakistani, Bangladeshi, Indian, Sri Lankan, Kashmiri) | BMI 30+ (no condition) · BMI 27+ (with condition) | BMI 27.5+ (no condition) · BMI 23+ (with condition) | Diabetes UK · WHO expert consultation on BMI in Asian populations · BHF South Asian heart health guidance |
| Black African / Black Caribbean / Somali | BMI 30+ · BMI 27+ | BMI 27.5+ · BMI 23+ | Elevated cardiovascular and T2D risk at lower BMIs compared to white European reference |
| Chinese / East Asian | BMI 30+ · BMI 27+ | BMI 27.5+ · BMI 23+ | WHO Asian BMI consultation · elevated metabolic risk at lower BMI |
| Middle Eastern / North African / Arab (including Yemeni, Somali) | BMI 30+ · BMI 27+ | BMI 27.5+ · BMI 23+ | Elevated T2D and cardiovascular risk at lower BMIs |
At Slinic, these adjusted thresholds are applied automatically when you state your ethnic background at assessment. You do not need to know the specific numbers or advocate for yourself. A Bangladeshi patient in Tower Hamlets with BMI 25 and type 2 diabetes qualifies for Mounjaro at Slinic under adjusted criteria — even though the standard BMI 27+ threshold would not apply to them.
Type 2 Diabetes and the Fastest NHS Route in 2026
For T2D patients, 2026 is the most significant year in NHS weight loss medicine. The April 2026 QOF pathway means T2D patients potentially have the fastest NHS route of any group — bypassing the 12–36 month tier 3 queue entirely if their practice has adopted the pathway.
Mounjaro’s dual licence is uniquely powerful for T2D patients. It is the only UK weight loss medication approved for both weight management AND type 2 diabetes treatment simultaneously. Clinical data from SURPASS-2 (NEJM 2021) demonstrates 15mg Mounjaro reduces HbA1c by an average of 2.58 percentage points — the strongest HbA1c reduction of any approved T2D treatment in published clinical trials — alongside 22.5% average weight loss.
Cardiovascular Disease and the April 2026 Wegovy Pathway
The SELECT trial enrolled patients with established cardiovascular disease — specifically prior MI, stroke, or peripheral arterial disease. Semaglutide 2.4mg reduced the composite endpoint of cardiovascular death, non-fatal MI, and non-fatal stroke by 20% over 34 months. This is a landmark result: no previous weight loss medication had demonstrated this level of cardiovascular benefit.
NICE’s April 2026 approval for this pathway means that patients who have had a heart attack, stroke, or TIA, and have BMI 27+ and no T2D, now have a legitimate fast-track NHS route for Wegovy at GP level. The most important areas for this pathway in the UK are Liverpool (highest CVD mortality of any major English city), Glasgow (highest CVD mortality of any major UK city), and the Black Country.
NHS vs Private — The Complete 2026 Comparison
| Factor | NHS tier 3 | NHS April 2026 GP routes | Private — Slinic |
|---|---|---|---|
| BMI threshold | 35+ with condition | 27+ (CVD route) · T2D (QOF route) | 30+ or 27+ with 1 condition (ethnic adjusted: 27.5+ / 23+) |
| Access speed | 12–36 months from GP referral | Potentially weeks — varies by practice adoption | 24–48 hours from assessment to delivery |
| Cost (England) | £9.90/item (free with exemptions) | £9.90/item (free with exemptions) | £139–£285/month Mounjaro · £99.99–£209.99 Wegovy · £4.99 delivery |
| Cost (Scotland) | Free | Free | Same fixed 2026 prices as England |
| Clinical monitoring | Tier 3 multidisciplinary team | GP and practice team | Free monthly check-ins with Slinic superintendent pharmacist |
| Free starter pack | Via tier 3 service | Via GP | ✅ Yes — needles and sharps bin with first order |
| Can run simultaneously | ✅ Yes — all three NHS routes and Slinic private can run simultaneously. No route conflicts with another. | ||
The Counterfeit Warning Every Patient Must Read
Social media, unregistered online sellers, and gym-based sellers are the primary distribution channels for counterfeit Mounjaro and Wegovy. These products are not MHRA-licensed, have unknown contents, and have caused hospitalisations across the UK.
Always verify your provider before ordering any weight loss injection: Check the GPhC register at pharmacyregulation.org. Slinic is GPhC No. 1033729. Any provider who cannot provide a GPhC number should be refused. Never purchase from social media, unregistered websites, or any seller who cannot provide verifiable GPhC registration.
Frequently Asked Questions — NHS Weight Loss Injections 2026
Can I get Mounjaro on the NHS in 2026?
Yes — through two NHS routes. Route 1 (tier 3 weight management): BMI 35+ with at least one qualifying condition. GP refers you to your ICB’s tier 3 service. Waiting time 12–36 months by region. Route 3 (April 2026 QOF T2D pathway): if you have type 2 diabetes and your GP practice has adopted the QOF tirzepatide pathway, your GP can prescribe Mounjaro directly — potentially in weeks rather than months. Private Mounjaro through Slinic starts from £139/month with no waiting list. Both routes can run simultaneously.
Can I get Wegovy on the NHS in 2026?
Yes — through two NHS routes. Route 1 (tier 3 weight management): same eligibility as Mounjaro — BMI 35+ with qualifying conditions, 12–36 months wait. Route 2 (April 2026 cardiovascular GP pathway): if you have BMI 27+, established cardiovascular disease (prior MI, stroke/TIA, or PAD), and no T2D, your GP can prescribe Wegovy directly following NICE’s April 2026 guidance. This may take weeks rather than months. Ask your GP today if you qualify. Private Wegovy through Slinic starts from £99.99/month — no waiting list. Start your eligibility check here.
What is the difference between Mounjaro and Wegovy on the NHS?
Both are approved through tier 3 weight management. Key differences: Mounjaro produces greater average weight loss (22.5% vs 14.9% at maintenance doses in head-to-head SURMOUNT-5 trial). Wegovy has the April 2026 NICE cardiovascular approval (20% MACE reduction in SELECT trial) — allowing GP direct prescribing for patients with established CVD and no T2D. Mounjaro has the QOF T2D pathway — allowing GP direct prescribing for T2D patients. Mounjaro holds the unique dual licence for both weight management and T2D treatment simultaneously.
Will the NHS pay for my Mounjaro or Wegovy?
In Scotland: yes — all NHS prescriptions are free in Scotland. In England: yes, at the standard NHS prescription charge of £9.90 per item (each pen). Many patients qualify for exemptions and pay nothing: patients with type 2 diabetes (medical exemption certificate), patients aged 60 or over, patients on qualifying benefits. An NHS Prescription Prepayment Certificate (PPC) caps annual prescription costs at approximately £111.60/year — significantly less than the cost of multiple pens per year. Check NHS PPC eligibility here.
Does being on the NHS waiting list stop me getting private Mounjaro?
No. Being on the NHS tier 3 waiting list and receiving private Mounjaro or Wegovy simultaneously is entirely compatible. Your NHS waiting list position is unaffected by what you do privately. This is confirmed by NHS England guidance and is the basis of the bridge strategy. When your NHS appointment arrives, you simply transition to NHS supply — typically at your current dose, with no requirement to restart from the lowest dose. Your Slinic clinical records provide the NHS team with a full treatment history.
What if I don’t meet the NHS BMI threshold?
For tier 3 (NHS Route 1), the BMI threshold is 35+. If your BMI is below 35 but above 30, or between 27–29.9 with a qualifying condition, you don’t qualify for tier 3 but may qualify for private prescribing at Slinic. If you are from a South Asian, Black African/Caribbean, Chinese, or Middle Eastern background, Slinic’s adjusted BMI thresholds apply: BMI 27.5+ without a condition, or BMI 23+ with a condition. For Route 2 (April 2026 CVD pathway), the threshold is BMI 27+ with established CVD and no T2D. For Route 3 (QOF T2D), the threshold depends on the practice’s implementation of the pathway.
How do I ask my GP for weight loss injection treatment?
Three specific questions to ask your GP: (1) “Can you refer me to the NHS tier 3 weight management service for Mounjaro or Wegovy prescribing?” — start the NHS clock regardless of other routes. (2) If you have established CVD: “Am I eligible for the NICE April 2026 cardiovascular semaglutide (Wegovy) prescribing pathway?” (3) If you have T2D: “Has your practice adopted the QOF tirzepatide (Mounjaro) T2D prescribing pathway?” Bring your weight and relevant medical history to the appointment. If your GP is unfamiliar with the April 2026 changes, reference NICE TA1060 (cardiovascular) and the NHS QOF 2026/27 guidance for T2D.
Can I get weight loss injections on the NHS if I only want to lose a few stone?
NHS tier 3 requires BMI 35+ — so “a few stone” depends on your starting height and weight. Calculate your BMI at nhs.uk/live-well/healthy-weight/bmi-calculator. If BMI is below 35, tier 3 doesn’t apply. However, the April 2026 NHS routes have lower thresholds (BMI 27+ for the cardiovascular and potentially the T2D routes) for specific clinical groups. Private Slinic prescribing starts at BMI 30+ without a condition, or BMI 27+ with a qualifying condition. The amount of weight you want to lose is not a criterion — clinical eligibility is based on your starting BMI and health conditions, not weight loss goals.
External Resources — NHS and Clinical Links
- NICE TA1026 — Tirzepatide for managing overweight and obesity (June 2025)
- NICE TA875 — Semaglutide for managing overweight and obesity (March 2023)
- NICE guidance — Semaglutide for cardiovascular risk reduction (April 2026)
- NHS England — Quality and Outcomes Framework 2026/27
- GPhC Register — Slinic verification (GPhC No. 1033729)
- MHRA — Counterfeit weight loss injection seizures 2025
- SURMOUNT-1 — Jastreboff AM et al. Tirzepatide for Obesity. NEJM 2022
- SELECT — Lincoff AM et al. Semaglutide and Cardiovascular Outcomes. NEJM 2023
- SURMOUNT-5 — Garvey WT et al. Tirzepatide vs Semaglutide. NEJM 2025
- NHS Prescription Prepayment Certificate — cap annual costs at £111.60/year
- Diabetes UK — South Asian communities and T2D risk
- WHO — BMI in Asian populations expert consultation
Related Guides on Slinic
Mounjaro NHS 2026 — Full Guide
NICE TA1026, QOF T2D pathway, regional waiting times
Cheapest Mounjaro UK 2026
Full verified price comparison — all major UK providers
Mounjaro vs Wegovy UK 2026
Head-to-head comparison — SURMOUNT-5 trial data
Weight Loss Injections London 2026
All 5 NHS London ICBs — borough-level waiting times
Weight Loss Injections Manchester 2026
All 10 GM districts — 12–24 month waits, Oldham ethnic BMI
Weight Loss Injections Birmingham 2026
NHS Birmingham and Solihull + Black Country ICB — 9.5% T2D
Weight Loss Injections Leeds 2026
Bradford highest T2D in England — West Yorkshire ICB all 5 areas
Weight Loss Injections Edinburgh 2026
NHS Lothian — free Scottish prescriptions, SMC governance
Weight Loss Injections Glasgow 2026
NHSGGC — highest CVD mortality UK, free Scottish prescriptions
Weight Loss Injections Liverpool 2026
NHS Cheshire and Merseyside — 18–30 month wait, CVD crisis
Start While You Wait — No NHS Queue at Slinic
Same MHRA-licensed Mounjaro and Wegovy as the NHS · Fixed 2026 prices · GPhC No. 1033729 · NHS-contracted · Free monthly clinical check-ins · Next-day to every UK postcode including all Scottish postcodes
- ✅ Mounjaro 2.5mg £139 through 15mg £285 — 22.5% average weight loss (SURMOUNT-1)
- ✅ Wegovy 0.25mg £99.99 through 2.4mg £209.99 — NICE CVD approved April 2026
- ✅ Free starter pack · Free monthly check-ins · £4.99 delivery · No subscription · No minimum term
- ✅ Starting private does not affect your NHS waiting list position
